Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 63
    Published on September 25, 2016


Study To Prevent Gestational Diabetes Recurrence

A study by researchers from the University of Western Australia, Perth shows stationary cycling exercise program started at 14 weeks of gestation didn't prevent the reappearance of gestational diabetes (GD). But researchers found improved maternal fitness and decreased psychological distress. Researchers say daily physical exercise can prevent type 2 diabetes (T2D). But study results are not showing clear in the case of gestational diabetes (GD). King Edward Memorial Hospital in Perth reports that risk of reappearance of gestational diabetes (GD) is 55 percent. Kym Guelfi, PhD and his colleagues studied 180 pregnant women and the study was funded by the National Health and Medical Research Council, Australia. The results were reported in Obstetrics & Gynecology.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Link Between Gestational Diabetes And Depression
2. Study Of Gestational Diabetes (GD)
3. Storing Body Fat More efficiently
4. Partnership Between Lifescan And WellDoc
5. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca

 

 

About Semaglutide GLP-1 Class Drug

SUSTAIN 6 trial results announced during the 52nd meeting of EASD, 2016 shows that GLP-1 class diabetes drug semaglutide reduces heart disease by 26 percent and stroke by 39 percent. A total of 3,297 diabetes patients from 20 countries for 104 weeks participated in SUSTAIN 6 trial study. Dr. Steven Marso was the lead author of the study and SUSTAIN 6 trial results were published in the New England Journal of Medicine.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Treatment With Semaglutide Pill
2. Trials Of GLP-1 (exenatide extended-release) And Farxiga (dapagliflozin)
3. Hormones GLP-1 And PYY
4. Device To Release Drugs In Eye
5. Device To Predict Diabetes

 

Semaglutide : Semaglutide a GLP-1 class drug increases the body's insulin production when blood sugar levels are raised. This drug is once in a week drug manufactured by Novo Nordisk to control glycaemic levels and weight loss in adults with type 2 diabetes (T2D). Novo Nordisk is working on to offer semaglutide as a pill instead of injection.

 

About Afrezza Cost Effective Insulin Drug

FDA approved, prescription-based Afrezza diabetes drug is a very rapidly absorbing (in the bloodstream) and fast-acting insulin, inhalable type from the United States based company MannKind Corporation. Both type 1 (T1D) and type 2 diabetes (T2D) patients can use this drug to control blood sugar levels. It is a cost-effective and close to human insulin. The insulin in the blood reaches peak level in 12 to 15 minutes and stay active for up to 180 minutes or 3 hours. Afrezza showed lower incidents of hypoglycemia in "AFFINITY 1" trial as afrezza completes its work early and active for up to 180 minutes or 3 hours only. So afrezza can be referred to "INsulin" and "OUTsulin". Few important points


  • Diabetic ketoacidosis cannot be treated with afrezza
  • The effectiveness of afrezza drug on patients who smoke is not known
  • Effectiveness and safeness of afrezza drug on diabetes patients below 18 years of age is not known
  • Afrezza should not be used in place of long-acting insulin. Type 1 diabetes (T1D) patients can use afrezza drug along with long-acting insulin
  • Afrezza may cause sudden lung problems (bronchospasms). So diabetes patients should avoid this drug if they are suffering from chronic lung problems such as asthma or COPD (chronic obstructive pulmonary disease)
  • Afrezza drug should not be taken during low blood sugar (hypoglycemia) periods
  • Diabetes patient should avoid if he is allergic to regular insulin or with afrezza

Possible side effects with afrezza are

  • Low blood sugar or hypoglycemia
  • May affect lung function and the patient should check lung function periodically
  • May show severe allergic reaction throughout the body such as rashes, breathing problem, sweating and the patient should seek immediate medical attention
  • The patient may face low potassium problem (hypokalemia)
  • Taking some diabetes medicines such as thiazolidinediones (TZDs) pills along with afrezza may cause heart failure in some people.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. About Fast-Acting Insulin Drug NovoRapid
2. Discovery Of Fast-Acting Insulin Of Conus Geographus
3. Device To Detect Deadly Ketones
4. About Revita DMR Device
5. About Continuous Glucose Monitoring (CGM) Devices

 

Ketoacidosis : Insulin is required for the body to move sugar from the bloodstream into the living cells. Sometimes the body can not use glucose (sugar converted from food) as a fuel source as there is no insulin production or insufficient insulin in the blood. At this body condition, the body uses body fat as fuel (in place of sugar in the blood) and releases waste products called ketones. When ketones levels cross unsafe levels, a diabetic individual is in diabetic ketoacidosis (DKA) condition. Risk factors for a type 1 diabetes (T1D) individual leading to diabetic ketoacidosis are

  • Not taking insulin doses
  • Body injury
  • Infection due to bacteria or virus
  • A serious illness
  • Surgery

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.